Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: J Cyst Fibros. 2019 Jun 27;19(3):407–414. doi: 10.1016/j.jcf.2019.06.008

Table 1.

Cohort Characteristics

Treatment Prescribed at Index No Antibiotics
N (%)
Oral and/or Inhaled
Antibiotics
N (%)
IV AntibioticsaN
(%)
Overall
N (%)
Number of Patients (%) 3,059 (21.4%) 8,774 (61.5%) 2,432 (17.0%) 14,265
Age Group (years)
   <6 663 (21.7%) 1631 (18.6%) 199 (8.2%) 2493 (17.5%)
   6 to <13 592 (19.4%) 2264 (25.8%) 395 (16.2%) 3251 (22.8%)
   13 to <18 436 (14.3%) 1512 (17.2%) 453 (18.6%) 2401 (16.8%)
   18 to <26 594 (19.4%) 1601 (18.2%) 629 (25.9%) 2824 (19.8%)
   ≥26 774 (25.3%) 1766 (20.1%) 756 (31.1%) 3296 (23.1%)
Female 1483 (48.5%) 4352 (49.6%) 1323 (54.4%) 7158 (50.2%)
Race
   Caucasian 2881 (94.2%) 8221 (93.7%) 2292 (94.2%) 13394 (93.9%)
   African American 100 (3.3%) 329 (3.7%) 75 (3.1%) 504 (3.5%)
   Other 78 (2.5%) 224 (2.6%) 65 (2.7%) 367 (2.6%)
Hispanic Ethnicityb 267 (9.0%) 692 (8.2%) 206 (8.7%) 1165 (8.5%)
Insurance Status
 Private 1869 (61.1%) 5251 (59.8%) 1266 (52.1%) 8386 (58.8%)
 Medicare/Medicaid 1117 (36.5%) 3342 (38.1%) 1106 (45.5%) 5565 (39.0%)
 Other 17 (0.6%) 62 (0.7%) 26 (1.1%) 105 (0.7%)
 Missing 56 (1.8%) 119 (1.4%) 34 (1.4%) 209 (1.5%)
Nutrition Status
Underweight 261 (8.5%) 720 (8.2%) 417 (17.1%) 1398 (9.8%)
Adequate 1962 (64.1%) 6025 (68.7%) 1649 (67.8%) 9636 (67.5%)
Overweight 483 (15.8%) 1280 (14.6%) 236 (9.7%) 1999 (14.0%)
Missing 353 (11.5%) 749 (8.5%) 130 (5.3%) 1232 (8.6%)
Time from Baseline to Index Clinic Visit (days)
 ≤30 475 (15.5%) 964 (11.0%) 535 (22.0%) 1974 (13.8%)
 31 to 90 1256 (41.1%) 3665 (41.8%) 1149 (47.2%) 6070 (42.6%)
 ≥91 1328 (43.4%) 4145 (47.2%) 748 (30.8%) 6221 (43.6%)
CF-related Diabetes 539 (17.6%) 1407 (16.0%) 731 (30.1%) 2677 (18.8%)
CFTR Mutation Class
   Only 1 to 3 2136 (69.8%) 6478 (73.8%) 1864 (76.6%) 10478 (73.5%)
   Any 4 and 5 294 (9.6%) 695 (7.9%) 157 (6.5%) 1146 (8.0%)
   Other 559 (18.3%) 1443 (16.4%) 364 (15.0%) 2366 (16.6%)
   Unknown 70 (2.3%) 158 (1.8%) 47 (1.9%) 275 (1.9%)
FEV1 % Predicted at Index
   Not Applicable <6 years old 663 (21.7%) 1631 (18.6%) 199 (8.2%) 2493 (17.5%)
   ≤40 279 (9.1%) 634 (7.2%) 572 (23.5%) 1485 (10.4%)
   41 to ≤70 678 (22.2%) 2068 (23.6%) 863 (35.5%) 3609 (25.3%)
   71 to ≤100 970 (31.7%) 3069 (35.0%) 513 (21.1%) 4552 (31.9%)
   >100 237 (7.7%) 765 (8.7%) 64 (2.6%) 1066 (7.5%)
   Missing among ≤6 year olds 232 (7.6%) 607 (6.9%) 221 (9.1%) 1060 (7.4%)
Absolute Change in FEV1 % Predicted Between Baseline and Index
   Not Applicable <6 years old 663 (21.7%) 1631 (18.6%) 199 (8.2%) 2493 (17.5%)
   Increase 499 (16.3%) 1260 (14.4%) 268 (11.0%) 2027 (14.2%)
   0 - <10% decrease 1100 (36.0%) 3145 (35.8%) 901 (37.0%) 5146 (36.1%)
   ≥10% decrease 400 (13.1%) 1685 (19.2%) 695 (28.6%) 2780 (19.5%)
   Missing among ≥6 year olds 397 (13.0%) 1053 (12.0%) 369 (15.2%) 1819 (12.8%)
Microbiology (≥1 positive culture in year prior to Index)
Any culture performed in last year of care 3,017 (98.6%) 8,071 (99.2%) 2,418 (99.4%) 14,136 (99.1%)
Pseudomonas aeruginosa 1462 (48.5%) 4129 (47.5%) 1577 (65.2%) 7168 (50.7%)
Methicillin-resistant Staphylococcus aureus 341 (11.3%) 1287 (14.8%) 316 (13.1%) 1944 (13.8%)
Other bacteria, including NTM 1058 (35.1%) 2983 (34.3%) 489 (20.2%) 4530 (32.0%)
Negative cultures 156 (5.2%) 302 (3.5%) 36 (1.5%) 494 (3.5%)
ABPA 138 (4.5%) 318 (3.6%) 127 (5.2%) 583 (4.1%)
Prior-year IV-treated PEx
   0 1996 (65.3%) 5679 (64.7%) 806 (33.1%) 8481 (59.5%)
   1 582 (19.0%) 1864 (21.2%) 650 (26.7%) 3096 (21.7%)
   2 234 (7.6%) 697 (7.9%) 367 (15.1%) 1298 (9.1%)
   ≥3 247 (8.1%) 534 (6.1%) 609 (25.0%) 1390 (9.7%)
PEX within 90 days of baseliine 524 (17.1%) 1349 (15.4%) 753 (31.0%) 2626 (18.4%)
a

Treatment with IV antibiotics defined as any treatment within 14 days of Index clinic visit

b

Missing = 531